Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B virus and age-related diseases. Leveraging our expertise in structure-based drug design and our innovative drug discovery engine, we have developed a robust pipeline of eight drug candidates that disrupt complex and difficult-to-target protein-protein interactions (PPIs), and next-generation tyrosine kinase inhibitors (TKIs). Our PPI drug candidates are designed to treat cancer and other diseases by restoring the normal function of key apoptotic pathways, including the Bcl-2/Bcl-xL, MDM2-p53 and IAP pathways, which play a pivotal role in regulating apoptosis. We are also developing next-generation TKIs to treat diseases for high unmet medical needs. Our compounds are being developed for use as a single agent or in combination with other therapies.
To pioneer a new class of medicines that can address the most difficult-to-treat diseases – and improve the lives of patients in China and globally
To become a world-leading, science-driven biophar-maceutical company